Taiwan has started administering its first domestically-developed COVID-19 immunization Medigen amid criticisms. President Tsai Ing-wen supported the distribution by getting the principal shot. The country’s health ministry allowed the authority of the antibody’s emergency utilization last month despite not having finished phase three trials yet. The company guarantees that the immunization has no significant safety concerns and the antibodies made are “no worse than” the vaccines rolled out by AstraZeneca. “We have done so many experiments, everyone has seen how safe our vaccine is. There are so few side effects, almost no fever and so on. So I think everyone can rest assured,” Medigen’s Chief Executive Officer Charles Chen said.

The country’s vaccination endeavors were delayed because of postponed delivery and hesitancy among its people. Resistance party Kuomintang (KMT) blames the vaccine as dangerous and was presented too soon in the market. Two individuals from the party sought a court to revoke the endorsement because of inadequate testing. Nonetheless, 700,000 residents signed up for the Medigen immunization. It requires a second dose 28 days after the primary shot. The public authority has ordered 5 million doses but declared that it will not force individuals to get the vaccine. Under 5% of Taiwan’s populace of 23.5 million are completely vaccinated, and approximately 40% are yet to get the subsequent dose.